Rallybio (RLYB) Total Current Liabilities (2020 - 2026)
Rallybio (RLYB) posted Total Current Liabilities of $4.1 million for Q1 2026, down 1.97% sequentially from $4.2 million in Q4 2025, and up 5.88% YoY from $3.9 million in Q1 2025.
Rallybio (RLYB) Total Current Liabilities (2020 - 2026) Analysis & Trends
Rallybio has reported Total Current Liabilities for 7 years, with the latest figure at $4.1 million in Q1 2026.
- Quarterly Total Current Liabilities rose 5.88% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 5.88% YoY) and the FY2025 annual result came in at $4.2 million, down 32.35% from the prior year.
- Total Current Liabilities fell to $4.1 million in Q1 2026 per RLYB's latest filing, from $4.2 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $12.2 million in Q2 2024 and troughed at $3.9 million in Q1 2025.
- A 5-year average of $7.5 million and a median of $7.3 million in 2022 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 64.01% in 2022, then tumbled 61.23% in 2025.
- Over 5 years, Total Current Liabilities stood at $10.7 million in 2022, then declined by 13.78% to $9.3 million in 2023, then tumbled by 32.61% to $6.2 million in 2024, then plunged by 32.35% to $4.2 million in 2025, then slipped by 1.97% to $4.1 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $4.1 million, $4.2 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 630.93 Mn |
| 10 | Rallybio | 96.60 Mn | 96.60 Mn | - | 3.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.57 Mn |
| Mar 31, 2026 | 4.14 Mn |
| Dec 31, 2025 | 4.22 Mn |
| Sep 30, 2025 | 4.52 Mn |
| Jun 30, 2025 | 5.04 Mn |
| Mar 31, 2025 | 3.91 Mn |
| Dec 31, 2024 | 6.24 Mn |
| Sep 30, 2024 | 8.19 Mn |
| Jun 30, 2024 | 12.16 Mn |
| Mar 31, 2024 | 10.09 Mn |
| Dec 31, 2023 | 9.26 Mn |
| Sep 30, 2023 | 9.40 Mn |
| Jun 30, 2023 | 8.05 Mn |
| Mar 31, 2023 | 6.80 Mn |
| Dec 31, 2022 | 10.74 Mn |
| Sep 30, 2022 | 11.30 Mn |
| Jun 30, 2022 | 7.28 Mn |
| Mar 31, 2022 | 5.80 Mn |
| Dec 31, 2021 | 6.55 Mn |
| Sep 30, 2021 | 7.34 Mn |